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Cardiopulmonary Support and Physiology Pandalai et alAcute b-blockade prevents myocardial b-adrenergic
receptor desensitization and preserves early ventricular
function after brain death
Prakash K. Pandalai, MD,a Kelly M. McLean, MD,a,b Christian F. Bulcao, MD, MBA,a Jodie Y. Duffy, PhD,a,b
Karen M. D'Souza, PhD,a Walter H. Merrill, MD,a Jeffrey M. Pearl, MD,b and Shahab A. Akhter, MDaObjective: b-Adrenergic receptor desensitization through activation of the G protein–
coupled receptor kinase 2 is an important mechanism of early cardiac dysfunction
after brain death. We hypothesized that acute b-blockade can prevent myocardial
b-adrenergic receptor desensitization after brain death through attenuation of
G protein–coupled receptor kinase 2 activity, resulting in improved cardiac function.
Methods: Adult pigs underwent either sham operation, induction of brain death, or
treatment with esmolol (b-blockade) for 30 minutes before and 45 minutes after brain
death (n 5 8 per group). Cardiac function was assessed at baseline and for 6 hours
after the operation. Myocardial b-adrenergic receptor signaling was assessed 6 hours
after operation by measuring sarcolemmal membrane adenylate cyclase activity,
b-adrenergic receptor density, and G protein–coupled receptor kinase 2 expression
and activity.
Results: Baseline left ventricular preload recruitable stroke work was similar among
sham, brain death, and b-blockade groups. Preload recruitable stroke work was signif-
icantly decreased 6 hours after brain death versus sham, and b-blockade resulted in
maintenance of baseline preload recruitable stroke work relative to brain death and
not different from sham. Basal and isoproterenol-stimulated adenylate cyclase activ-
ities were preserved in the b-blockade group relative to the brain death group and were
not different from the sham group. Left ventricular G protein–coupled receptor kinase
2 expression and activity in the b-blockade group were markedly decreased relative to
the brain death group and similar to the sham group. b-Adrenergic receptor density
was not different among groups.
Conclusion: Acute b-blockade before brain death attenuates b-adrenergic receptor
desensitization mediated by G protein–coupled receptor kinase 2 and preserves early
cardiac function after brain death. These data support the hypothesis that acute
b-adrenergic receptor desensitization is an important mechanism in early ventricular
dysfunction after brain death. Future studies with b-blocker therapy immediately after
brain death appear warranted.
T
he incidence of heart failure (HF) continues to increase in the United States and
worldwide. Despite advances in medical therapy, the average survival for
patients diagnosed with HF is approximately 5 years.1 Although the most
effective long-term therapy for end-stage HF is cardiac transplantation, this remains
an extremely limited option because of the donor organ shortage. Adding to donor
limitations, nearly 25% of potential heart donors are found to have significantly
depressed myocardial function without evidence of structural heart disease and there-
fore are not considered for organ procurement. The etiology of ventricular dysfunc-
tion after brain death (BD) is likely multifactorial, and previously reported
hypotheses include ischemic injury,2 direct catecholamine-induced myocardial
injury,3 and impaired b-adrenergic receptor (b-AR) signaling.4
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PAbbreviations and Acronyms
AD 5 adenylate cyclase
BD 5 brain death
b-AR 5 b-adrenergic receptor
cAMP 5 cyclic adenosine monophosphate
GRK 5 G protein–coupled receptor kinase
HF 5 heart failure
PRSW 5 preload recruitable stroke work
G protein–coupled receptor kinases (GRKs) are serine–
threonine kinases that phosphorylate agonist-occupied G
protein–coupled receptors, leading to receptor-effector
uncoupling, or desensitization. GRK2, the primary GRK
expressed in the heart, plays an important role in regulating
b-AR signaling and cardiac function.5,6 We recently demon-
strated in a porcine model that impaired b-AR signaling after
BD is mediated by elevated GRK2 activity and contributes to
the cardiac dysfunction seen after BD.7 We hypothesized that
the catecholamine surge resulting from BD leads to activa-
tion of myocardial b-ARs and subsequent activation of
GRK2. This in turn leads to desensitization of myocardial
b-ARs, decreased intracellular cyclic adenosine monophos-
phate (cAMP) production, and depressed ventricular func-
tion. In this study, we hypothesized that this effect of BD
on early cardiac function might be prevented by inhibiting
activation of GRK2 with intravenous b-blocker therapy.
We used a validated porcine model of BD and ventricular
dysfunction to study the effects of esmolol administration
on cardiac function and the myocardial b-AR signaling
system.
Materials and Methods
All animals received humane care and treatment in compliance
with the ‘‘Principles of Laboratory Animal Care’’ formulated by
the National Society for Medical Research and in accordance
with the ‘‘Guide for the Care and Use of Laboratory Animals’’
(www.nap.edu/catalog/5140.html). The animal care and use com-
mittee at Children’s Hospital Research Foundation also approved
the protocol.
Model of Donor Heart Dysfunction
Crossbred adolescent pigs (20-35 kg) were anesthetized with
ketamine (20 mg/kg intramuscularly) and acepromazine (1.1 mg/
kg intramuscularly), intubated, and ventilated. A 22F Fogarty occlu-
sion catheter (Baxter Healthcare Corporation CardioVascular
Group, Irvine, Calif) and an open-lumen pressure catheter (Med-
tronic, Inc, Minneapolis, Minn) were placed into the subdural space
through a frontoparietal burr hole. A LaserFlo laser Doppler blood
perfusion monitor (Vasamedics LLC, St Paul, Minn) was inserted
directly into the brain. Animals were assigned to one of the follow-
ing three protocols (n 5 8 per group): sham operation without BD
(sham group), induced BD (BD group), and induced BD with
concomitant b-blockade (BB group). BB animals were treated
with 200-mg/(kg $ min) esmolol (a b1-selective b-blocker with rapidThe Journal of Thoonset, very short duration of action, and no significant intrinsic
sympathomimetic or membrane stabilizing activity) for 30 minutes
before induction of BD and for 45 minutes after BD.
Through a median sternotomy, piezoelectric ultrasound crystals
(Sonometrics Corporation, London, Ontario, Canada) were placed
in three axes on the heart to monitor cardiac function. Pressure trans-
ducer–tipped 2F or 3F catheters (Millar Instruments, Inc, Houston,
Tex) were placed in both ventricles and the pulmonary artery. The
subdural balloon was then inflated with 25 mL water during 1 min-
ute to induce BD, which was confirmed by electroencephalography
and correlated with changes in laser-detected blood flow. Cardiopul-
monary function and intracranial pressure were monitored continu-
ously throughout the experiment. Left ventricular end-diastolic
volume was kept constant. After 6 hours of BD, the animals were
killed with sodium pentobarbital, and myocardial specimens were
snap frozen in liquid nitrogen and stored at 280C.
Analysis of Cardiac Function
Cardiosoft data analysis software (Sonometrics) was used to
determine the derivative of the change in pressure over time and
pressure–volume relationships. Preload recruitable stroke work
(PRSW) was calculated from data collected during transient inferior
vena caval occlusion.8
Adenylate Cyclase Activity
Cardiac sarcolemmal membranes (20 mg protein) were incubated for
15 minutes at 37C with [a-32P]adenosine triphosphate under basal
conditions, 1024-mol/L isoproterenol (INN isoprenaline), or 10-
mmol/L sodium fluoride. The cAMP production was quantified by
standard methods described previously.9
Radioligand Binding
Total b-AR density was determined by incubating 25 mg cardiac
sarcolemmal membranes with a saturating concentration of iodine
125–labeled cyanopindolol and 20-mmol/L alprenolol hydrochlo-
ride (INN alprenolol) to define nonspecific binding as previously
described.7 Sarcolemmal membrane samples from all three groups
were run in triplicate with 80-pmol/L [125I]cyanopindolol and
1024-mol/L isoproterenol in 250 mL binding buffer (50-mmol/L
N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid [pH 7.3],
5-mmol/L magnesium chloride, and 0.1-mmol/L ascorbic acid).
The reactions were performed at 37C for 1 hour and then filtered
over GF/C glass fiber filters (Whatman plc, Maidstone, United
Kingdom) that were washed twice and counted in a gamma counter.
Data were analyzed by nonlinear least squares curve fitting (Prism;
GraphPad Software, Inc, San Diego, Calif).
Protein Immunoblotting
Determination of expression of GRK2 in myocardial sarcolemmal
membranes was performed on tissue extracts as previously de-
scribed.7 Tissue was homogenized in ice-cold lysis buffer
(25-mmol/L tris[hydroxymethyl]aminomethane hydrochloride [pH
7.5], 5-mmol/L EDTA, 5-mmol/L ethyleneglycol-bis-[b-aminoethy-
lether]-N,N,N0,N0-tetraacetic acid, 10-mg/mL leupeptin, 20-mg/mL
aprotinin, and 1-mmol/L phenylmethylsulfonyl fluoride). Nuclei
and tissue were separated by centrifugation at 800g for 20 minutes.
The crude supernatant was then centrifuged at 20,000g for 20 min-
utes. Sedimented proteins (membrane fraction) were resuspended in
50-mmol/L N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acidracic and Cardiovascular Surgery c Volume 135, Number 4 793
Cardiopulmonary Support and Physiology Pandalai et al
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of myocardial levels of GRK2 with a polyclonal antibody (Santa
Cruz Biotechnology, Inc, Santa Cruz, Calif) was performed on an
equal amount of protein from membrane extracts (70 mg) electrophor-
esed through 10% tris(hydroxymethyl)aminomethane/glycine gels
and transferred to nitrocellulose. Membranes were blocked in 5%
nonfat dried milk in 0.1% polysorbate 20 in phosphate-buffered saline
solution for 1 hour at room temperature. The protein was visualized
with a horseradish peroxidase–linked secondary antibody and
enhanced chemiluminescence detection (Amersham Pharmacia
Biotech AB, Uppsala, Sweden).
GRK Activity by Rhodopsin Phosphorylation
The membrane fractions of the myocardial extracts were used to
determine GRK activity. Extracts (120 mg protein) were incubated
with rhodopsin-enriched rod outer-segment membranes in reaction
buffer containing the following: 10-mmol/L magnesium chloride,
20-mmol/L tris(hydroxymethyl)aminomethane hydrochloride,
2-mmol/L EDTA, 5-mmol/L ethyleneglycol-bis-(b-aminoethy-
lether)-N,N,N0,N0-tetraacetic acid, and 0.1-mmol/L adenosine
triphosphate (containing [a-32P]adenosine triphosphate), as previ-
ously described.6 After incubation in white light for 15 minutes
at room temperature, reactions were quenched with ice-cold lysis
buffer, and preparations were centrifuged for 15 minutes at
13,000g. Sedimented proteins were resuspended in 25 mL
protein–gel–loading dye and treated with 12% sodium dodecylsul-
fate–polyacrylamide gel electrophoresis. Phosphorylated rhodop-
sin was visualized by autoradiography of dried polyacrylamide
gels and quantified with a Molecular Dynamics PhosphorImager
(Molecular Dynamics, Inc, Sunnyvale, Calif).
Statistical Analysis
Repeated-measures analysis of variance was used to analyze serial
data across time within treatment groups. Analyses were conducted
with StatView 4.01 software (SAS Institute, Inc, Cary, NC). Exper-
imental groups were compared with the Student t test or 1-way
analysis of variance, as appropriate. The Bonferroni test was applied
to all significant analysis of variance results with SigmaStat software
(Systat Software, Inc, Point Richmond, Calif). All results are
expressed as mean 6 SEM.
Results
In Vivo Cardiac Physiology
Baseline left ventricular PRSW was similar among BD,
sham, and BB groups (BD 43.3 6 3.1 vs sham 43.7 6
5.5 vs BB 38.2 6 1.9, P . .05; Figure 1, A). PRSW was
significantly decreased 6 hours after BD in the BD group
relative to the sham group (21.4 6 3.4 vs 36.2 6 3.8,
P , .05; Figure 1, A), indicating a marked decline in left
ventricular systolic function after BD. In contrast, b-block-
ade resulted in preservation of left ventricular PRSW at 6
hours after BD (BB 38.2 6 1.9 vs BD 21.4 6 3.4, P , .05;
Figure 1, A). Consistent with these findings, left ventricular
dP/dtmin, a measure of diastolic function, was significantly
impaired 6 hours after BD relative to the sham group and
maintained in the BB group (BD 2250 6 38 mm Hg/s
vs sham 2549 6 71 mm Hg/s vs BB 2596 6 81 mm794 The Journal of Thoracic and Cardiovascular Surgery c AprHg/s, P , .05; Figure 1, B). There was marked improve-
ment in the BB group relative to the BD group (2596 6
81 mm Hg/s vs 2250 6 38 mm Hg/s, P , .05). These
indices of systolic and diastolic function indicate impaired
myocardial function after BD and are consistent with previ-
ously described animal models.4,5 Improvement in both left
ventricular PRSW and left ventricular dP/dtmin suggests
preservation of both systolic and diastolic function after
BD in animals treated with esmolol.
Figure 1. A, Left ventricular preload recruitable stroke work
(PRSW) at baseline and after sham operation (Sh, circles, n 5
8), induction of brain death (BD, squares, n 5 8), and induction
of brain death with b-blocker therapy (BB, triangles, n5 8). Aster-
isk indicates P< .05 versus brain death and P> .05 versus sham.
B, Left ventricular dP/dtmin at baseline and after sham operation
(Sh, circles, n 5 8), induction of brain death (BD, squares,
n 5 8), and induction of brain death with b-blocker therapy (BB,
triangles, n 5 8). Asterisk indicates P < .05 versus brain death
and P > .05 versus sham.il 2008
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To study the effects of BD on myocardial b-AR signaling, we
assessed receptor–effector coupling in sarcolemmal mem-
branes from hearts in BD, sham, and BB groups by measur-
ing adenylate cyclase (AC) activity. Basal AC activity was
blunted in the BD group relative to the sham and BB groups
(BD 25.7 6 2.0 pmol cAMP/[mg $ min] vs sham 58.8 6 4
pmol cAMP/[mg $ min] vs BB 55.4 6 12 pmol cAMP/[mg
$ min], P , .001; Figure 2). Isoproterenol-stimulated AC
activity was also significantly lower after BD than in the
sham and BB groups (BD 55.6 6 8 pmol cAMP/[mg $
min] vs sham 124 6 20 pmol cAMP/[mg $ min] vs BB
124 6 27 pmol cAMP/[mg $ min], P , .005; Figure 2).
AC activity stimulated by sodium fluoride, which induces
maximal activity of AC by Gas stimulation, was similar in
all groups (474 6 88 pmol cAMP/[mg $ min] vs 381 6
120 pmol cAMP/[mg $ min] vs 310 6 76 pmol cAMP/[mg
$ min], P . .05), indicating that the G protein–AC moiety
is intact in all groups. This blunting of basal and agonist-
stimulated AC activity after BD suggests that uncoupling
of myocardial b-ARs occurs early after BD. The preservation
of AC activity in the animals that underwent b-blockade also
indicates that b-AR receptor desensitization can be acutely
inhibited with this medical therapy.
Myocardial b-AR Density and G Protein Expression
Total myocardial sarcolemmal membrane b-AR density was
measured 6 hours after induction of BD or sham operation,
and no differences were noted among groups (sham 121.56
31 fmol/mg vs BD 132.15 6 14.7 fmol/mg vs BB 141.7 6
33.2 fmol/mg, P . .05; Figure 3). Acute b-blockade did
not have an effect on myocardial b-AR density. These data
indicate that b-AR desensitization rather than downregula-
tion is an important mechanism of decreased ventricular
Figure 2. Myocardial sarcolemmal membrane adenylate cyclase
activity 6 hours after sham operation (Sh, white columns, n 5 8),
induction of brain death (BD, black columns, n5 8), and induction
of brain death with b-blocker therapy (BB, gray columns, n 5 8).
cAMP, Cyclic adenosine monophosphate; ISO, 1024-mol/L isopro-
terenol;NaF, 50-mmol/L sodium fluoride. Asterisk indicates P< .03
versus sham and b-blockade. Crosshatch indicates P< .05 versus
brain death and sham.The Journal of Thorfunction after BD. Myocardial expression of the G protein
subunits Gas and Gai were measured by protein immunoblot-
ting, and there was no difference among groups before induc-
tion of BD or sham operation or at 6 hours after BD (data not
shown).
Myocardial GRK Expression and Activity
Left ventricular GRK2 expression in the sarcolemmal
membrane fraction 6 hours after BD was elevated relative
to the sham group (20.1 6 1 densitometry units [DU] vs
13.1 6 1.2 DU, P , .05; Figure 4). After treatment with
esmolol, there was a significant decrease in membrane
GRK2 expression in the BB group relative to the BD group
at 6 hours (11.4 6 1 DU vs 20.1 6 1 DU, P , .05]. Total
myocardial GRK2 expression was not different among the
three groups before or after induction of BD or sham opera-
tion (data not shown). The increase in GRK2 expression in
the membrane fraction after BD correlates with an increase
in myocardial membrane GRK2 activity measured by rho-
dopsin phosphorylation in BD versus BB animals (218.6 6
8.1 DU vs 130.26 4.4 DU, P, .02; Figure 5). We examined
left ventricular myocardial membrane expression of GRK5,
the other GRK expressed in the heart, by protein immuno-
blotting and found no difference among the three groups
(data not shown). Thus the attenuation of sarcolemmal mem-
brane GRK2 expression and activity after intravenous
b-blockade suggests that GRK2 activity and b-AR desensiti-
zation can be acutely inhibited with this medical approach.
Discussion
Potential donor heart dysfunction presents an additional
limitation to cardiac transplantation for patients with end-
stage HF. Impaired myocardial b-AR signaling has been
shown to be an important mechanism, because this receptor
system is critical to the regulation of cardiac function. We
Figure 3. Myocardial sarcolemmal membrane b-adrenergic re-
ceptor (b-AR) density 6 hours after sham operation (Sh, white col-
umns, n5 8), induction of brain death (BD, black columns, n5 8),
and induction of brain death with b-blocker therapy (BB, gray col-
umns, n 5 8, each group performed in triplicate). No statistical
differences among groups were seen.acic and Cardiovascular Surgery c Volume 135, Number 4 795
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CSPFigure 4. Myocardial sarcolemmal membrane G protein–coupled receptor kinase 2 (GRK2) expression 6 hours after
sham operation (Sh, white columns, n 5 8), induction of brain death (BD, black columns, n 5 8), and induction of
brain death with b-blocker therapy (BB, gray columns, n5 8, each group performed in triplicate). Asterisk indicates
P< .05 versus sham. Crosshatch indicates P< .05 versus BD and P> .05 versus sham. Plus sign represents positive
control.have previously shown in an experimental model that uncou-
pling, or desensitization, of myocardial b-ARs after BD
results from activation of GRK2.7 GRK2 is a member of
the GRK family of serine–threonine kinases, which phos-
phorylate and inhibit further signaling through specific
agonist-occupied receptors. GRK2, the primary GRK ex-
pressed in the heart, is an important mediator of ventricular
function in vivo.5,10 The primary targets of GRK2 phosphor-
ylation in the heart are b-ARs. The focus of this study was to
investigate more specifically the significance and mechanism
of impaired b-AR signaling in ventricular function after BD
and to determine whether acute b-blockade could inhibit
b-AR desensitization and maintain cardiac function in an
experimental model of BD and ventricular dysfunction.
Our data demonstrate that impaired b-AR signaling is
an important cause of early ventricular dysfunction after
BD. The primary mechanism for this appears to be in-
creased GRK2 activity, leading to desensitization of
b-ARs and impaired receptor–effector coupling. BD is
associated with an acute catecholamine surge, and circulat-
ing levels of the adrenal hormones norepinephrine and epi-
nephrine are greatly elevated.11 This leads to significantly
enhanced myocardial b-AR stimulation and the hyperten-
sive and tachycardic phenotype characteristic of BD.796 The Journal of Thoracic and Cardiovascular Surgery c AprGRK2 activity is then elevated, leading to early impair-
ment in b-AR signaling and thus ventricular dysfunction.
Although this impaired b-AR signaling resulting from
GRK2 activation would be expected to be transient after
the catecholamine surge, our data suggest that GRK2 activ-
ity is increased and myocardial b-AR desensitization is
present at least as long as 6 hours after the induction of
BD. Studies of this mechanism of early donor heart dys-
function need to be performed at longer intervals after
BD to determine whether impaired b-AR signaling persists
at 18 to 24 hours.
We have previously shown that long-term left ventricular
assist device support in patients with end-stage HF can
restore myocardial b-AR signaling to normal levels and
that the primary mechanism is through decreases in GRK2
expression and activity, which appear to be due to a decline
in circulating catecholamine levels after normalization of
hemodynamics.12 This is the only demonstration to date of
an intervention that can regulate ventricular GRK2 activity
and effect b-AR signaling in human beings. Previously pub-
lished work from our laboratory showed that long-term
b-blocker treatment in mice can lower myocardial GRK2
activity and lead to enhanced b-AR signaling in the heart.13
The effects of acute b-blockade on this signaling pathwayil 2008
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PFigure 5. G protein–coupled receptor kinase 2 (GRK2) activity in myocardial sarcolemmal membrane preparations 6
hours after sham operation (Sh, white columns, n5 8), induction of brain death (BD, black columns, n5 8), and in-
duction of brain death with b-blocker therapy (BB, gray columns, n 5 8, each group performed in triplicate). Rho,
Rhodopsin. Asterisk indicates P< .02 versus sham. Crosshatch indicates P< .01 versus BD and P> .05 versus sham.and ventricular function have not been studied. We adminis-
tered esmolol, a cardioselective b1-AR blocker with a very
short duration of action, before the induction of BD to deter-
mine whether the acute b-AR desensitization associated with
the catecholamine surge could be prevented or diminished,
leading to preservation of normal ventricular function early
after BD. Acute b-blockade did in fact prevent myocardial
b-AR desensitization after BD, as measured by left ventricu-
lar sarcolemmal membrane basal and isoproterenol-stimu-
lated AC activity. AC activity in the esmolol-treated group
was preserved and did not differ from that in sham-operated
control subjects. In addition, there was no increase in myo-
cardial GRK2 activity in animals receiving esmolol before
BD relative to the 3-fold elevation in GRK2 activity present
in the BD group, which did not receive esmolol. Our data
demonstrate for the first time that acute b-blockade can
prevent myocardial b-AR desensitization in the setting of
increased b-agonist stimulation resulting from inhibition of
GRK2 activity. This led to preservation of left ventricular
function after BD relative to animals that did not receive
esmolol treatment before BD and did have significant ven-
tricular dysfunction. These data also highlight the importance
of impaired b-AR signaling as a mechanism in poor myocar-
dial function after BD.
These experiments were performed as a proof-of-principle
study to determine more specifically the significance of
impaired b-AR signaling in cardiac dysfunction after BD.The Journal of ThoFor that reason, animals were treated with esmolol before
induction of BD. Further studies should be performed to eval-
uate the efficacy of acute b-blocker therapy immediately after
the onset of BD, which is a more clinically applicable situa-
tion. Although the catecholamine surge associated with BD
is transient, we have shown that elevated GRK2 activity and
impaired b-AR signaling are present for as long as 6 hours
after BD, with continued ventricular dysfunction. It appears
reasonable to hypothesize on the basis of these findings that
b-blocker therapy administered just after the onset of BD may
be effective in the preservation of myocardial b-AR signaling
and cardiac function. In addition to b-blockade, direct inhibi-
tion of GRK2 activity may be possible in the future through
use of a previously described peptide inhibitor of this ki-
nase.5,14 Inhibition of GRK2 activity through gene transfer
of this peptide in vitro and in vivo resulted in significantly en-
hanced b-AR signaling and cardiac myocyte or ventricular
contractility.14-17 Strategies to inhibit b-AR desensitization
by GRK2 may represent a novel approach to preventing early
donor heart dysfunction, potentially increasing the number of
organs that can be procured for cardiac transplantation.
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